公开(公告)号：US12016910B2

公开(公告)日：2024-06-25

申请号：US17043192

申请日：2019-04-11

申请人： ENTEROME S.A.

发明人： Laurent Chene ,  Christophe Bonny ,  Francesco Strozzi

IPC分类号： A61K39/00 ,  A61P35/00

CPC分类号： A61K39/001119 ,  A61K39/00115 ,  A61K39/001152 ,  A61K39/001154 ,  A61P35/00 ,  A61K2039/55566

摘要： The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, fragments of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.

公开(公告)号：US20240033336A1

公开(公告)日：2024-02-01

申请号：US18184000

申请日：2023-03-15

申请人： Boehringer Ingelheim International GmbH

发明人： Elodie BELNOUE ,  Madiha DEROUAZI ,  Paul ADAM ,  Imgard Rita Maria HOFMANN ,  Ralf LEONHARDT ,  Samuel LUKOWSKI ,  Tobias NOLDEN ,  Francesca TRAPANI

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/001164 ,  A61K39/001162 ,  A61K39/0011 ,  A61K39/4611 ,  A61K39/4632 ,  A61K39/4631 ,  A61K39/001182 ,  A61K39/001154 ,  A61K39/464464 ,  A61K39/464462 ,  A61K39/4644 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/70 ,  A61K2039/5256 ,  A61K2039/54

摘要： The present invention relates to tumor antigens encoded in a 5′-upstream open reading frame (uORF) within the 5′ UTR of different mRNAs. Compositions and peptides comprising such tumor antigens and a virus encoding such tumor antigens are provided. The present invention also relates to the use of such compositions, peptides and viruses in the treatment of cancer.

公开(公告)号：US20230212244A1

公开(公告)日：2023-07-06

申请号：US18063418

申请日：2022-12-08

申请人： Immatics Biotechnologies GmbH

发明人： Oliver SCHOOR ,  Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Jens FRITSCHE ,  Harpreet SINGH

IPC分类号： C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/113 ,  C07K14/725 ,  C07K16/30

CPC分类号： C07K14/4748 ,  A61K39/0011 ,  A61K39/001154 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3046 ,  C07K16/3076 ,  C12N5/0636 ,  C12N15/1138 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K2317/34 ,  C12N2310/16 ,  C12N2501/50

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190218308A1

公开(公告)日：2019-07-18

申请号：US16370726

申请日：2019-03-29

申请人： INNATE PHARMA

发明人： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC分类号： C07K16/40 ,  A61P35/00 ,  G01N33/574 ,  C07K16/28 ,  A61K9/00

CPC分类号： C07K16/2896 ,  A61K39/001154 ,  A61K2039/507 ,  A61K2039/545 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/92 ,  C12N9/14

摘要： The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.

公开(公告)号：US20240307516A1

公开(公告)日：2024-09-19

申请号：US18550854

申请日：2021-08-31

申请人： IO BIOTECH APS

发明人： Mads Hald ANDERSEN

IPC分类号： A61K39/00 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4245 ,  A61K31/517 ,  A61P35/00 ,  C07K16/28 ,  G01N33/569

CPC分类号： A61K39/001154 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4245 ,  A61K31/517 ,  A61K39/001111 ,  A61P35/00 ,  C07K16/2818 ,  C12Y113/11052 ,  G01N33/56972 ,  A61K2039/505 ,  A61K2039/55516

摘要： The present disclosure relates to the field of cancer treatment and prevention. The present disclosure further relates to (a) a first immune checkpoint polypeptide or a polynucleotide encoding the same; (b) a second immune checkpoint polypeptide or a polynucleotide encoding the same; and (c) an immune checkpoint inhibitor. The disclosure also relates to compositions comprising one or more of (a), (b) and/or (c), methods of use, and kits comprising same. The disclosure also relates to methods for stratifying cancer patients and methods for monitoring the treatment response.

公开(公告)号：US12084512B2

公开(公告)日：2024-09-10

申请号：US16481108

申请日：2018-02-01

申请人： Novo Nordisk A/S

发明人： Karina Thorn ,  Bjarne Gram Hansen ,  Laust Bruun Johnsen ,  Mikkel Nors Harndahl ,  Zhiru Yang ,  Henrik Oestergaard ,  Per J. Greisen ,  Morten Groenbech Rasch ,  Jianhe Chen ,  Haisun Zhu ,  Rong Zhou ,  Prafull S. Gandhi

IPC分类号： C07K16/36 ,  A61K39/00 ,  A61P7/04

CPC分类号： C07K16/36 ,  A61K39/001154 ,  A61P7/04 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/75 ,  C07K2317/92

摘要： The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.

公开(公告)号：US20230338492A1

公开(公告)日：2023-10-26

申请号：US18318912

申请日：2023-05-17

申请人： The Regents of the University of Michigan

发明人： Qiao Li

IPC分类号： A61P35/00 ,  A61K39/00 ,  C12N5/0784

CPC分类号： A61K39/001154 ,  A61P35/00 ,  C12N5/0639 ,  A61K45/06

摘要： The present invention relates to compositions, systems, kits, and methods for generating and using ALDH1 antigen-pulsed dendritic cells (DCs). In certain embodiments, initial DCs are pulsed in vitro with a composition comprising ALDH1A1 and/or ALDH1A3 immunogenic peptide(s) to generate ALDH1 antigen-pulsed DCs, wherein the composition is free of tumor cells, cell lysates, and full-length ALDH1 proteins. In some embodiments, the ALDH1 antigen-pulsed DCs are administered to a subject in order to at least partially treat cancer (e.g., to kill at least some cancer stem cells in the subject).

公开(公告)号：US20190247482A1

公开(公告)日：2019-08-15

申请号：US16306352

申请日：2017-06-02

申请人： Ultimovacs AS

发明人： Gustav Gaudernack ,  Audun Tornes

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  A61P35/04

CPC分类号： A61K39/001157 ,  A61K39/0011 ,  A61K39/00115 ,  A61K39/001154 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/70 ,  A61P35/00 ,  A61P35/04 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/76 ,  A61K2300/00

摘要： A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.

公开(公告)号：US11878053B2

公开(公告)日：2024-01-23

申请号：US16922604

申请日：2020-07-07

申请人： IO Biotech ApS

发明人： Mads Hald Andersen

IPC分类号： A61K48/00 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  C07K14/725 ,  C07K14/74 ,  C12N9/02 ,  G01N33/564

CPC分类号： A61K39/001154 ,  A61K39/39 ,  A61K45/06 ,  C07K14/7051 ,  C07K14/70539 ,  C12N9/0069 ,  C12Y113/11011 ,  G01N33/564 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/55566 ,  G01N2333/90241

摘要： The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan 2,3-dioxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.

公开(公告)号：US20230256070A1

公开(公告)日：2023-08-17

申请号：US18153643

申请日：2023-01-12

申请人： NGM Biopharmaceuticals, Inc.

发明人： Kalyani Mondal ,  Betty Chan Li ,  Yu Chen ,  Taruna Arora ,  Hugo Matern ,  Wenyan Shen

IPC分类号： A61K39/00 ,  C07K16/28

CPC分类号： A61K39/001154 ,  C07K16/28 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/75 ,  G01N33/66

摘要： The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.